3. Treatment-naive PCV patients 4. BCVA at study entry from 25 to 80 ETDRS letters (Snellen Equivalent 20/320 to 20/25) 5. Presence of PCV in the study eye assessed by the Central Reading Centre based on multimodal retinal imaging (CFP, SD-OCT, FA and ICGA), including the presence of active polyps on ICGA, with or without branching vascular network. Subfoveal involvement is required, with intraretinal or subretinal fluid and/or subfoveal PED seen on SD-OCT. 6. Greatest linear dimension of the lesion of ≤ 5400 μm, assessed by FA/ICGA angiography. 7. Women must be post-menopausal for at least 12 months prior to trial entry, or surgically sterile, or in case of child-bearing potential, women must be using highly effective method of birth control (i.e. one that results in a failure rate less than 1% per year when used consistently and correctly, such as, combined hormonal contraception, progestogen-only hormonal contraception, intrauterine devices (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, and sexual abstinence). 8. Ability to provide written informed consent. 9. Ability to return for all study visits.
Exclusion criteria: 1. Active ocular or periocular infection or inflammation in the study eye. 2. Uncontrolled intraocular pressure in the study eye. 3. Ocular condition in the study eye likely to impact vision and confound study outcomes (e.g. vitreomacular traction, epiretinal membrane with severe retinal folds, ocular inflammation, retinal vascular diseases like diabetic retinopathy or diabetic macular edema). 4. Presence of centromacular scarring or atrophy indicating irreversible BCVA loss. 5. Prior treatment of the study eye with any anti-VEGF agents 6. Systemic use of anti-VEGF products within 3 months prior to the study entry. 7. Previous intraocular surgery, macular laser treatment, PDT, or intraocular steroids in the study eye. 8. Known serious allergies or history of hypersensitivity to fluorescein, indocyanine green, verteporfin or components used on Eylea® formulation. 9. Subject with a condition (such as advanced, severe or unstable disease or its treatment) or subject in a situation which may put him/her at significant risk, confound the study results or significantly interfere with the subject's participation in the study. 
